{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Intrahepatic+Cholangiocarcinoma", "query": { "condition": "Locally Advanced Intrahepatic Cholangiocarcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Intrahepatic+Cholangiocarcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T07:49:50.125Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04708067", "title": "Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Intrahepatic Cholangiocarcinoma", "Metastatic Intrahepatic Cholangiocarcinoma", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8" ], "interventions": [ { "name": "Bintrafusp Alfa", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-08-31", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-05-22T07:49:50.125Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04708067" }, { "nct_id": "NCT05422690", "title": "The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Induction Chemotherapy Triplet Therapy", "type": "DRUG" }, { "name": "Concurrent Y-90 treatment", "type": "RADIATION" }, { "name": "Consolidation Doublet Therapy:", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2024-06-12", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-05-22T07:49:50.125Z", "location_count": 1, "location_summary": "Fairfax, Virginia", "locations": [ { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05422690" }, { "nct_id": "NCT06160752", "title": "Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Cholangiocarcinoma", "Intrahepatic Cholangiocarcinoma", "Solid Tumor", "Metastatic Cholangiocarcinoma" ], "interventions": [ { "name": "Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles", "type": "DRUG" }, { "name": "Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-11-22", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2024-10-03", "last_synced_at": "2026-05-22T07:49:50.125Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06160752" }, { "nct_id": "NCT05655949", "title": "Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bile Duct Cancer", "Cholangiocarcinoma", "Cholangiocarcinoma Non-resectable", "Cholangiocarcinoma Metastatic", "Metastatic Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Yttrium-90", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-13", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-05-22T07:49:50.125Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05655949" }, { "nct_id": "NCT06058663", "title": "Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Intrahepatic Cholangiocarcinoma", "Oligometastatic Intrahepatic Cholangiocarcinoma", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Angiography", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" }, { "name": "Yttrium-90 Microsphere Radioembolization", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2024-06-06", "completion_date": "2028-11-30", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-22T07:49:50.125Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06058663" }, { "nct_id": "NCT03267940", "title": "Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma Non-resectable", "Cholangiocarcinoma, Intrahepatic", "Cholangiocarcinoma, Extrahepatic", "Gallbladder Adenocarcinoma" ], "interventions": [ { "name": "PEGPH20", "type": "DRUG" }, { "name": "CIS", "type": "DRUG" }, { "name": "GEM", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2017-10-02", "completion_date": "2019-11-11", "has_results": true, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-05-22T07:49:50.125Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03267940" }, { "nct_id": "NCT06140134", "title": "Liver Transplantation in Intrahepatic Cholangiocarcinoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Intrahepatic Cholangiocarcinoma", "Cholangiocarcinoma, Intrahepatic" ], "interventions": [ { "name": "Liver Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 30, "start_date": "2023-12-15", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-05-22T07:49:50.125Z", "location_count": 2, "location_summary": "Newark, New Jersey", "locations": [ { "city": "Newark", "state": "New Jersey" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06140134" }, { "nct_id": "NCT02254681", "title": "Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "low dose radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Allina Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 6, "start_date": "2014-09", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-05-22T07:49:50.125Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02254681" }, { "nct_id": "NCT04163900", "title": "Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Biliary Tract Cancer" ], "interventions": [ { "name": "NUC-1031", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NuCana plc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 773, "start_date": "2019-12-24", "completion_date": "2022-04-05", "has_results": true, "last_update_posted_date": "2023-05-24", "last_synced_at": "2026-05-22T07:49:50.125Z", "location_count": 29, "location_summary": "Tucson, Arizona • Whittier, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Whittier", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04163900" }, { "nct_id": "NCT01525069", "title": "Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma", "Liver Neoplasms" ], "interventions": [ { "name": "Floxuridine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2012-04-03", "completion_date": "2022-08-02", "has_results": false, "last_update_posted_date": "2022-08-10", "last_synced_at": "2026-05-22T07:49:50.125Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01525069" } ] }